Comparison

PCI-32765

Item no. CT-PCI327-100
Manufacturer ChemieTek
CASRN 936563-96-1
Amount 100 mg
Quantity options 10 mg 100 mg 200 mg 50 mg 500 mg
Category
Type Inhibitors
Specific against other
Purity >99.5% (HPLC at 214 and 254nm), 100% optical purity (Chiral HPLC), [α]<sup>20</sup><sub>D</sub> = -128 <sup>o</sup> (c 0.87, Chloroform)
Citations 1. H. Zhang, et al, In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1, Br J Pharmacol. 2014 Dec;171(24):5845-57,
2. LA Honigberg, et al, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias Ibrutinib
Available
Storage Conditions
Store at 0°C (short term), -20°C (long term), desiccated
Brief Description
B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation. Bruton's Tyrosine Kinase (BTK) is an essential element of the BCR signaling pathway. Containment of BTK blocks BCR signaling and induces apoptosis. PCI-32765 is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.5 nM.
Original QC Data
HPLC-MS, 1HNMR, Chiral HPLC, and Quantitative Elemental Analysis
Solubility
Soluble in DMSO

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close